Clover Health's 2025 Performance and 2026 Outlook in Medicare Advantage

Clover Health Investments, Corp. (Nasdaq: CLOV) has unveiled its financial performance for the fourth quarter and full year of 2025. The firm plans a discussion on these results during a conference call at 5:00 p.m. ET. According to CEO Andrew Toy, Clover Health's resilience and strategic execution have propelled significant progress in the Medicare Advantage sector, driving a notable increase in membership. Toy anticipates achieving the company's first complete year of GAAP net income profitability by 2026, underscored by effective pricing and benefit structuring.

CFO Peter Kuipers highlighted Clover Health's financial agility in 2025, maintaining Adjusted EBITDA profitability and efficient medical cost management. Kuipers is bullish about 2026, projecting enhanced economic performance within cohorts, strong member retention, favorable rate environments, and sustained operational leverage, which will further membership expansion and financial success under GAAP guidelines.

Clover Health's 2026 financial outlook prioritizes Total revenues and Consolidated Gross profit, signifying a departure from prior metrics to better reflect consolidated business performance. Today's live conference call will provide additional insights into these financial results, with a webcast available on the Investor Relations site for post-call evaluation for an entire year. The company remains committed to improving healthcare access for Medicare beneficiaries, focusing on Clover Assistant technology to reduce costs and enhance service delivery.